However, precision becomes more critical because small measurement errors translate to larger dose differences
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide (marketed as Ozempic and Wegovy), have gained widespread attention for their effectiveness in treating type 2 diabetes and aiding in weight loss
Combined with weight loss itself, these effects can dramatically improve metabolic parameters
Mounjaro and Zepbound are both tirzepatide, again, same molecule, different indications
Conclusion Effectively using semaglutide for weight management and diabetes treatment requires a comprehensive approach that combines dietary adjustments, mindful lifestyle changes, and personalised professional guidance